Loading…
LXR Biotech, LLC, a drug manufacturer in Rochester Hills, Michigan, was found to have produced adulterated pharmaceutical products in violation of Current Good Manufacturing Practice (CGMP) regulations during a January 2023 FDA inspection. The company failed to adequately test drug components for identity, purity, strength, and quality, and did not validate or establish the reliability of component suppliers' test analyses at appropriate intervals, including failure to obtain or review suppliers' certificates of analysis. The FDA determined the firm's response was inadequate because while LXR Biotech stated it no longer manufactures drugs, it provided no specific corrective actions, preventive measures, or commitment to remove affected products from the market.